Predictive Value of Monocyte to High-Density Lipoprotein Cholesterol Ratio (MHR) in Schizophrenia Patients with Stable Coronary Artery Disease
Öz
Aim: We aimed to investigate whether monocyte/high density lipoprotein ratio (MHR) has a predictive value in patients with schizophrenia (SP) and in schizophrenia patients with stable coronary artery disease (SPCAD).
Material and Method: A total of 281 participants were enrolled in this cross-sectional study. Of the participants, 85 (Group 1) were diagnosed schizophrenia and stable coronary artery disease, and 92 (Group 2) were diagnosed only schizophrenia. 104 (Group 3) participants in the control group had no disease.
Results: MHR was highest in group 1 and higher in group 2 than in group 3 (18.91 (13.38-23.60) vs. 13.68 (11.11-16.66) vs. 12.50 (9.13-15.68), respectively; p<0.001 for both). Conversely, HDL was the lowest in group 1, while it was lower in group 2 than in group 3 (38.52 ± 9.45 vs. 42.76 ± 9.12 vs. 47.00 ± 11.87, respectively p<0.05 for both). The cutoff value of MHR for SPCAD was 12.77, with a sensitivity of 79% and a specificity of 43%. This value for SP was 10.73, with a sensitivity of 79% and a specificity of 50%.
Conclusion: High MHR which indicates an enhanced inflammation and oxidative stress was found to be a significant and independent marker in SP and SPCAD.
Anahtar Kelimeler
schizophrenia, Coronary artery disease, monocyte to high-density lipoprotein ratio, inflammation, oxidative stress
Proje Numarası
yok
Kaynakça
- McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia-An Overview. JAMA psychiatry. 2019:1-10.
- Liu J, Li M, Luo XJ, Su B. Systems-level analysis of risk genes reveals the modular nature of schizophrenia. Schizophrenia research. 2018;201:261-9.
- Trépanier MO, Hopperton KE, Mizrahi R, Mechawar N, Bazinet RP. Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review. Molecular psychiatry. 2016;21:1009-26.
- Gallego JA, Blanco EA, Husain-Krautter S, et al. Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis. Schizophrenia research. 2018;202:64-71.
- Karageorgiou V, Milas GP, Michopoulos I. Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis. Schizophrenia research. 2019;206:4-12.
- Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biological psychiatry. 2013;74:400-9.
- Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biological psychiatry. 2011;70:663-71.
- Guest PC. Insulin Resistance in Schizophrenia. Advances in experimental medicine and biology. 2019;1134:1-16.
- Leonard BE, Schwarz M, Myint AM. The metabolic syndrome in schizophrenia: is inflammation a contributing cause? Journal of psychopharmacology (Oxford, England). 2012;26:33-41.
- Karanikas E, Antoniadis D, Garyfallos GD. The role of cortisol in first episode of psychosis: a systematic review. Current psychiatry reports. 2014;16:503.